Penumbra to Highlight Peripheral Vascular Technologies at AIMsymposium and VEITHsymposium in New York

Final Results of Indigo^® System Multicenter PRISM Trial Will Be Presented

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced its presence at the upcoming 24^th AIMsymposium^® to be held November 14-17 and the 43^rd VEITHsymposium^® to be held November 15-19 in New York. Penumbra will highlight its peripheral vascular technologies, and final results of the multicenter PRISM study, designed to assess the safety and efficacy of the Indigo^® System for peripheral and visceral arterial thrombi and emboli, will be presented.

The Indigo System is a novel mechanical aspiration system for the removal of emboli and thrombi in the peripheral vasculature. PRISM, which began in 2014, evaluated the use of the Indigo System for patients with peripheral occlusions secondary to acute ischemia, incomplete reperfusion and procedure-related distal emboli, using primarily the system’s smaller size catheters. “Multicenter Retrospective Analysis Of Results Of Penumbra Indigo System For Mechanical Clot Aspiration From Arteries: How It Works, Indications, Vessel Sizes And Decreased Need For Lytics: The PRISM Registry” will be presented by Dr. James Benenati of Miami Cardiac & Vascular Institute (Florida) on Thursday, November 17, at 4:50 p.m. in Grand Ballroom West, 3rd Floor, Session 62.

Penumbra will showcase its growing portfolio of peripheral vascular technologies at its booth (#310 and 311 – 3rd Floor Promenade), including its latest enhancement to the Indigo System, the Advanced Separator, which is offered with the larger size separator and designed to be more robust and supportive for clot extraction in larger arteries and veins in the periphery. Penumbra will also feature its embolization product line: Ruby^® Coil, POD^®, POD Packing Coil and LANTERN^®, a low-profile, high flow coil delivery microcatheter.

Podium Presentations

Penumbra’s embolization and thrombectomy devices will be highlighted in several podium presentations throughout the week:

• “Use of the Indigo Device for Acute DVT: Replacing Thrombus Dissolution with Thrombus Extraction” will be presented by Dr. Patrick Muck of Good Samaritan Hospital (Cincinnati, Ohio) on Tuesday, November 15, at 2:30 p.m. in the Trianon Ballroom.
• “Advantages of The Indigo Thrombectomy Device from Penumbra to Treat ALI – How does it Get Clot Out More Effectively: Does It Have Disadvantages or Limitations” will be presented by Dr. Muck on Wednesday, November 16, at 3:40 p.m. in the Grand Ballroom West.
• “Why the Indigo Catheter Mechanical Thrombectomy System is A Better Way to Remove Clot and Debris from Blood Vessels and Decrease the Need for Lytic Drugs” will be presented by Dr. Frank Arko of Sanger Heart & Vascular Institute (Charlotte, North Carolina) on Thursday, November 17, at 4:56 p.m. in the Grand Ballroom West.
• “Value of Indigo Thrombus Aspiration System in Acute Limb Ischemia and Visceral Artery Thromboses or Emboli: Why it is a Game Changer” will be presented by Dr. George Adams of University of North Carolina Medical Center (Raleigh and Chapel Hill, North Carolina) on Thursday, November 17, at 5:02 p.m. in the Grand Ballroom West.
• “Use of the LANTERN Microcatheter and Ruby and POD Coils (Penumbra) for Arterial Embolization: What are Their Advantages and Limitations” will be presented by Dr. Aaron Fischman of Mount Sinai Medical Center (New York) on Thursday, November 17, at 5:14 p.m. in the Grand Ballroom West.

Company-Sponsored Events

Penumbra will host a lunch symposium on Wednesday, November 16, at noon at Gramercy Suite East, 2nd Floor, New York Hilton Midtown. The symposium will include presentations on Penumbra’s peripheral vascular technologies by Dr. Arko and Dr. Benenati.

Penumbra will also participate in hands-on workshops where physicians can join in discussions with experienced users and utilize Indigo System, Ruby Coil, POD, POD Packing Coil and LANTERN in simulated models:

• Wednesday, November 16: Venous Venous Venous™ Workshops at VEITHsymposium, Module 2: DVT Treatment (featuring Indigo System), 1-6 p.m., Americas Hall 2, 3rd Floor
• Thursday, November 17: AIMsymposium Workshops / Case Presentations, Concourse A, Concourse Level (featuring Indigo System, Ruby Coil, POD, POD Packing Coil and LANTERN)
  • 8-9 a.m. – PVD
  • 10-11 a.m. – Embolization
  • 11 a.m. to noon – IVC Filters
  • 2-3 p.m. – TACE / Radioembolization
  • 5-6 p.m. – Venous / Lymphatic Intervention

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra logo, Indigo, Ruby, POD and LANTERN are trademarks of Penumbra, Inc. Other trademarks are the property of their respective owners.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2015. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Source: Penumbra, Inc.